STUDY OF ORAL CCII IN TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS

口服CCII治疗活动性类风湿关节炎的研究

• 批准号: 6117917
• 负责人: MICHAEL H WEISMAN
• 金额: $ 1.46万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117917
• 关键词: antiarthritic agent; antiinflammatory agents; clinical research; collagen; drug screening /evaluation; human subject; human therapy evaluation; oral tolerance; rheumatoid arthritis; skeletal disorder chemotherapy

Compare clinical response to graded oral doses of CCII to placebo in patients with active rheumatoid arthritis, determine onset, magnitude and duration of beneficial clinical response, and determine safety and tolerability of doses and duration of treatment in patient population.

比较活动性类风湿关节炎患者口服分级剂量CCII与安慰剂的临床反应，确定有益临床反应的发作、程度和持续时间，并确定患者群体中剂量的安全性和耐受性以及治疗时间。